The Zhitong Finance App learned that Dutch biotech company Argenx SE (ARGX.US) agreed to acquire clinical-stage biopharmaceutical company Forte Biosciences (FBRX.US) with about US$2.2 billion in cash to expand its immunological drug product portfolio. Argenx said on Monday that it will buy Dallas-based Forte Biosciences for $77 per share, an offer that represents a 40% premium over the latter's closing price last Friday. Argenx said both companies' boards of directors have approved the deal. The deal is expected to close in the third quarter, subject to customary transaction conditions.

The Zhitong Finance App learned that Dutch biotech company Argenx SE (ARGX.US) agreed to acquire clinical-stage biopharmaceutical company Forte Biosciences (FBRX.US) with about US$2.2 billion in cash to expand its immunological drug product portfolio. Argenx said on Monday that it will buy Dallas-based Forte Biosciences for $77 per share, an offer that represents a 40% premium over the latter's closing price last Friday. Argenx said both companies' boards of directors have approved the deal. The deal is expected to close in the third quarter, subject to customary transaction conditions.